Study Information
Study Details
View study details on clinicaltrials.gov.
Locations
Clinical Trial FAQs
Information for patients and study volunteers, including frequently asked questions.
Description
This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib), in participants with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer who have developed resistance to adjuvant endocrine therapy.
Location: SIMR (Sacramento/Valley Area)
Please contact: SIMR@sutterhealth.org about Locally Advanced or Metastatic (pionERA)
Principal Investigator
Related Studies
Impact of COVID-19 on Cancer Care Management
Investigators: Monique de Bruin, M.D., MPH, Su-Ying Liang, Ph.D.
Breast Cancer Chemoprevention in Primary Care at Geisinger
Investigators: Xiaowei (Sherry) Yan, PhD, MS, External PI, Principal Investigator
Dana Farber 13-09-259 DCIS Registry
Investigator: Kristie A. Bobolis, M.D.